Addition of ruxolitinib in Graft‐versus‐Host disease prophylaxis for pediatric β‐Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study

Abstract

AbstractBackgroundTo evaluate the effect of addition of ruxolitinib in Graft‐versus‐Host Disease (GVHD) prophylaxis on pediatric patients with β‐thalassemia major after allogeneic hematopoietic stem cell transplantation(HSCT).MethodsThis retrospective study reviewed 49 consecutive β‐thalassemia major pediatric patients who underwent HSCT from unrelated or haploidentical donors from February 2018 to October 2022. All transplantation recipients received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short‐term methotrexate (MTX) as GVHD prophylaxis; while 27 of them in the ruxolitinib group had added ruxolitinib oral to GVHD prophylaxis regimen at 2.5 mg twice daily once successful engraftment after January 2020.ResultsThe outcome showed that the ruxolitinib group had a lower cumulative incidence than the control group regardless of acute GVHD (22.2% vs.40.9%; p = .153) or chronic GVHD (18.5% vs.40.9%; p = .072); especially, the incidence of grade III‐IV acute GVHD was reported significantly less frequently in ruxolitinib group than that of the control group (0 vs. 27.3%, p = .005). No significant difference was detected between the two groups in EBV (Epstein–Barr virus)/CMV (cytomegalovirus) reactivation and BKV (BK virus) infection (p = .703, 1.000, and .436, respectively). Twenty‐six patients (96.3%) in the ruxolitinib group were alive, while two patients (9.1%) in the control group died of intestinal acute GVHD. The 2‐year overall survival (OS) and thalassemia‐free survival (TFS) were both 96.296% in the ruxolitinib group, while both 90.909% in the control group.ConclusionThis study reveals that ruxolitinib prophylaxis is a promising option to decrease the incidence of grade III‐IV acute GVHD in pediatric patients with β‐thalassemia major.